Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.33 |
| ▸ | USP2 | O75604 | 2/20 | 0.33 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | LPAR3 | Q9UBY5 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4737247 | 1.00 | TSHR (0.34) | TSHRMAPTABCC4ALDH1A1USP2 | |
| SCHEMBL4737080 | 0.98 | TSHR (0.38) | TSHRMAPTABCC4ALDH1A1USP2 | |
| SCHEMBL3324577 | 0.98 | TSHR (0.38) | TSHRMAPTABCC4ALDH1A1USP2 | |
| SCHEMBL4785238 | 0.74 | NOS2 (0.44) | TSHRMAPTABCC4ALDH1A1USP2 | |
| SCHEMBL9353790 | 0.74 | — | — | |
| SCHEMBL9255164 | 0.73 | TSHR (0.42) | TSHRMAPTABCC4ALDH1A1USP2 | |
| Hydrochloric Acid SCHEMBL3322822 | 0.72 | NOS2 (0.42) | TSHRMAPTABCC4ALDH1A1USP2 | |
| SCHEMBL30040268 | 0.72 | TSHR (0.46) | TSHRMAPTABCC4ALDH1A1USP2 | |
| Hydrochloric Acid SCHEMBL3321961 | 0.71 | NOS2 (0.41) | TSHRMAPTABCC4ALDH1A1USP2 | |
| SCHEMBL11063317 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100120716-A1 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS AND USES THEREFOR | PHENOMIX CORPORATION (US) | 2010-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120716-A1 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS AND USES THEREFOR | PREP, HPN, PEPD | TSHR 3944/4885MAPT 3678/4885ABCC4 3054/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.